ProCE Banner Activity

Phase I Study of AMG 510, a Novel KRASG12C Inhibitor, in Advanced KRASG12C-Positive Solid Tumors

Slideset Download
Conference Coverage
AMG 510 showed a tolerable safety profile and preliminary antitumor activity in previously treated patients with KRASG12C-positive tumors, including NSCLC.

Released: June 05, 2019

Expiration: June 03, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro